Coya Therapeutics, Inc. (NASDAQ:COYA – Get Free Report) saw a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 173,600 shares, an increase of 7.3% from the August 31st total of 161,800 shares. Based on an average daily volume of 44,800 shares, the short-interest ratio is presently 3.9 days. Currently, 1.2% of the company’s stock are short sold.
Analyst Upgrades and Downgrades
A number of brokerages have commented on COYA. HC Wainwright began coverage on shares of Coya Therapeutics in a research report on Monday, September 16th. They issued a “buy” rating and a $18.00 price objective on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research report on Wednesday, June 5th. Finally, Rodman & Renshaw initiated coverage on shares of Coya Therapeutics in a research report on Thursday, June 13th. They issued a “buy” rating and a $18.00 target price on the stock.
Get Our Latest Stock Analysis on COYA
Coya Therapeutics Price Performance
Coya Therapeutics (NASDAQ:COYA – Get Free Report) last posted its earnings results on Monday, August 12th. The company reported ($0.19) EPS for the quarter. The company had revenue of $3.43 million for the quarter. As a group, sell-side analysts forecast that Coya Therapeutics will post -1.27 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. Gilbert & Cook Inc. purchased a new position in Coya Therapeutics during the 2nd quarter worth $61,000. Renaissance Technologies LLC purchased a new position in Coya Therapeutics during the 2nd quarter worth $101,000. Vanguard Group Inc. grew its position in Coya Therapeutics by 772.3% during the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after purchasing an additional 750,338 shares during the last quarter. Finally, Greenlight Capital Inc. grew its position in Coya Therapeutics by 172.2% during the 4th quarter. Greenlight Capital Inc. now owns 1,274,026 shares of the company’s stock worth $9,441,000 after purchasing an additional 805,959 shares during the last quarter. 39.75% of the stock is owned by hedge funds and other institutional investors.
Coya Therapeutics Company Profile
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Read More
- Five stocks we like better than Coya Therapeutics
- 3 Best Fintech Stocks for a Portfolio Boost
- Why Lennar Stock Could Be the Best Play in the Housing Market
- How to Use Stock Screeners to Find Stocks
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Using the MarketBeat Stock Split Calculator
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.